Argent BioPharma Limited (RGT.L)
- Previous Close
22.00 - Open
22.29 - Bid 21.00 x --
- Ask 23.00 x --
- Day's Range
21.00 - 22.40 - 52 Week Range
0.22 - 470.00 - Volume
444 - Avg. Volume
26,645 - Market Cap (intraday)
10.143M - Beta (5Y Monthly) 0.98
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide. Its principal product candidates include CimetrA, which is in phase II clinical trial for the treatment of SLE Lupus, anti-inflammatory, and SARS COVID-19; and CannEpil, which is in phase I clinical trial for refractory epilepsy and cerebral palsy; and CogniCann, which is in phase I clinical trial for the symptomatic relief of Dementia and Alzheimer. In addition, the company provides Irnican for brain cancer. The company was formerly known as MGC Pharmaceuticals Limited and changed it name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
mgcpharma.com.au--
Full Time Employees
June 30
Fiscal Year Ends
Sector
Related News
Performance Overview: RGT.L
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RGT.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RGT.L
Valuation Measures
Market Cap
9.60M
Enterprise Value
6.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.37
Price/Book (mrq)
14.21
Enterprise Value/Revenue
3.89
Enterprise Value/EBITDA
-0.42
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-58.96%
Return on Equity (ttm)
--
Revenue (ttm)
1.32M
Net Income Avi to Common (ttm)
-17.02M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
6.48M
Total Debt/Equity (mrq)
1,436.12%
Levered Free Cash Flow (ttm)
-6.57M